Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study.

Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D; Parkinson Study Group PRECEPT Investigators.

Neurology. 2014 May 20;82(20):1791-7. doi: 10.1212/WNL.0000000000000424. Epub 2014 Apr 23.

2.
3.
4.

Genome-wide variant by serum urate interaction in Parkinson's disease.

Nazeri A, Roostaei T, Sadaghiani S, Chakravarty MM, Eberly S, Lang AE, Voineskos AN.

Ann Neurol. 2015 Nov;78(5):731-41. doi: 10.1002/ana.24504. Epub 2015 Aug 29.

PMID:
26284320
5.

Does levodopa slow or hasten the rate of progression of Parkinson's disease?

Fahn S; Parkinson Study Group.

J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. Review.

PMID:
16222436
6.

Levodopa and the progression of Parkinson's disease.

Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group.

N Engl J Med. 2004 Dec 9;351(24):2498-508.

7.

Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism.

Tinazzi M, Antonini A, Bovi T, Pasquin I, Steinmayr M, Moretto G, Fiaschi A, Ottaviani S.

J Neurol. 2009 Jun;256(6):910-5. doi: 10.1007/s00415-009-5039-0. Epub 2009 Mar 1.

PMID:
19252795
8.

Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study.

Tinazzi M, Morgante F, Matinella A, Bovi T, Cannas A, Solla P, Marrosu F, Nicoletti A, Zappia M, Luca A, Di Stefano A, Morgante L, Pacchetti C, Minafra B, Sciarretta M, Dallocchio C, Rossi S, Ulivelli M, Ceravolo R, Frosini D, Cipriani A, Barbui C.

Schizophr Res. 2014 Feb;152(2-3):344-9. doi: 10.1016/j.schres.2013.11.028. Epub 2013 Dec 25.

PMID:
24369987
9.

Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT.

Varrone A, Sansone V, Pellecchia MT, Amboni M, Salvatore E, De Michele G, Filla A, Barone P, Pappatà S, Salvatore M.

Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1343-9. doi: 10.1007/s00259-008-0729-x. Epub 2008 Feb 19.

PMID:
18283454
10.

The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease.

Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, Bernardi G, Simonetti G, Stanzione P.

Eur J Nucl Med Mol Imaging. 2005 Dec;32(12):1452-6. Epub 2005 Sep 8.

PMID:
16151764
11.

Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT.

Nocker M, Seppi K, Donnemiller E, Virgolini I, Wenning GK, Poewe W, Scherfler C.

Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1012-20. doi: 10.1007/s00259-012-2100-5. Epub 2012 Mar 30.

PMID:
22460689
12.
13.

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.

Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, Oakes D, Seibyl J.

Neurology. 2001 Dec 11;57(11):2089-94.

PMID:
11739831
14.

Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K; PARS Investigators.

Neurology. 2014 Nov 4;83(19):1739-46. doi: 10.1212/WNL.0000000000000960. Epub 2014 Oct 8.

15.

Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.

Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, Seibyl JP.

Mov Disord. 1999 May;14(3):436-42.

PMID:
10348466
16.

[[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy.

Berding G, Brücke T, Odin P, Brooks DJ, Kolbe H, Gielow P, Harke H, Knoop BO, Dengler R, Knapp WH.

Nuklearmedizin. 2003 Feb;42(1):31-8.

PMID:
12601452
17.

Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial.

Jennings D, Eberly S, Oakes D, Seibyl J, Marek K, Shoulson I; Parkinson Study Group PRECEPT Investigators.

J Parkinsons Dis. 2014;4(4):629-38. doi: 10.3233/JPD-140383.

PMID:
25062961
18.

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.

Parkinson Study Group PRECEPT Investigators.

Neurology. 2007 Oct 9;69(15):1480-90. Epub 2007 Sep 19.

PMID:
17881719
19.

Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.

Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, Kim KM, Yoon KY, Lee MC, Lee SB.

Ann Neurol. 1998 Jun;43(6):792-800.

PMID:
9629849
20.

Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.

Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S.

Neurology. 2001 Jun 12;56(11):1559-64.

PMID:
11402115

Supplemental Content

Support Center